Binding epitopes and interaction structure of the neuroprotective protease inhibitor cystatin C with β-amyloid revealed by proteolytic excision mass spectrometry and molecular docking simulation

Journal of Medicinal Chemistry

Volumn 52, Issue 8, 2009, Pages 2420-2428

  Juszczyk, Paulina ^a,b   Paraschiv, Gabriela ^a   Szymanska, Aneta ^b   Kolodziejczyk, Aneta S ^b   Rodziewicz Motowidlo, Sylwia ^b   Grzonka, Zbigniew ^b   Przybylski, Michael ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[17-28]; CYSTATIN C; EPITOPE; NEUROPROTECTIVE AGENT; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR DOCKING; PROTEIN DEGRADATION; SIMULATION; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; BINDING SITES; CYSTATIN C; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURFACE PLASMON RESONANCE;

EID: 65249086686     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801115e     Document Type: Article

References (43)

1. Glenner, G. G.; Wong, C. W. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984, 122 , 1131-1135.
2. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297, 353-356.
3. Kang, J.; Lemaire, H. G.; Unterbeck, A.; Salbaum, J. M.; Masters, C. L. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325, 733-736.
4. Tanzi, R. E.; Gusella, J. F.; Watkins, P. C.; Brans, G. A.; St George- Hyslop, P. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987, 235, 880- 884.
5. Calero, M.; Rostagno, A.; Frangione, B.; Ghiso, J. Clusterin and Alzheimer's disease. Subcell. Biochem. 2005, 38 , 273-298.
6. Anderson, D. H.; Talaga, K. C.; Rivest, A. J.; Barron, E.; Hageman, G. S. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp. Eye Res. 2004, 78 , 243-256.
7. Bard, F.; Cannon, C.; Barbour, R.; Burke, R. L.; Games, D. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6 , 916-919.
8. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400, 173-177.
9. DeMattos, R. B.; Bales, K. R.; Cummins, D. J.; Dodart, J. C.; Paul, S. M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 , 8850- 8855.
10. Janus, C.; Pearson, J.; McLaurin, J.; Mathews, P. M; Jiang, Y. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408, 979-982.
11. Hock, C.; Konietzko, U.; Streffer, J. R.; Tracy, J.; Signorell, A. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38, 547-554.
12. McLaurin, J.; Cecal, R.; Kierstead, M. E.; Tian, X.; Phinney, A. L. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibriHogenesis. Nat. Med. 2002, 8 , 1263-1269.
13. Tian, X.; Cecal, R.; McLaurin, J.; Manea, M.; Stefanescu, R. Identification and structural characterisation of carboxy-terminal polypeptides and antibody epitopes of Alzheimer's amyloid precursor protein using high-resolution mass spectrometry. Eur. J. Mass Spectrom. (Chichester. Engl.) 2005, 11 , 547-556.
14. Du, Y.; Dodel, R.; Hampel, H.; Buerger, K.; Lin, S. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001, 57 , 801-805.
15. Du, Y.; Wei, X.; Dodel, R.; Sommer, N.; Hampel, H. Human antibeta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003, 126, 1935- 1939.
16. Dodel, R. C.; Du, Y.; Depboylu, C.; Hampel, H.; Frolich, L. Intravenous immunoglobulins containing antibodies against betaamyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75 , 1472-1474.
17. Stefanescu, R.; Iacob, R. E.; Damoc, E. N.; Marquardt, A.; Amstalden, E. Mass spectrometric approaches for elucidation of antigen-antibody recognition structures in molecular immunology. Eur. J. Mass Spectrom. (Chichester. Engl. ) 2007, 13 , 69-75.
18. Przybylski, M.; Stefanescu, R.; Manea, M., ; Bacher, M.; Dodel, R. Diagnosis and Treatment of Alzheimer's and Other Neurodementing Diseases. PCT Patent Appl. WO 2008/084402A2, July 17, 2008; University of Konstanz, University of Marburg.
19. Levy, E.; Sastre, M.; Kumar, A.; Gallo, G.; Piccardo, P. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J. Neuropathol Exp. Neurol. 2001, 60 , 94-104.
20. Rodziewicz-Motowidlo, S.; Wahlbom, M.; Wang, X.; Lagiewka, J.; Janowski, R. Checking the conformational stability of cystatin C and its L68Q variant by molecular dynamics studies: why is the L68Q variant amyloidogenic? J. Struct. Biol. 2006, 154 , 68-78.
21. Calero, M.; Pawlik, M.; Soto, C.; Castano, E. M.; Sigurdsson, E. M. Distinct properties of wild-type and the amyloidogenic human cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J. Neurochem. 2001, 77 , 628-637.
22. Levy, E.; Jaskolski, M.; Grabb, A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol. 2006, 16 , 60-70.
23. Selenica, M. L.; Wang, X.; Ostergaard-Pedersen, L.; Westlind- Danielsson, A.; Grabb, A. Cystatin C reduces the in vitro formation of soluble Abet al.-42 oligomers and protofibrils. Scand. J. Clin. Lab. Invest. 2007, 67 , 179-190.
24. Vattemi, G.; Engel, W. K.; McFerrin, J.; Askanas, V. Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloidbeta precursor protein in sporadic inclusion-body myositis muscles. J. Neurochem. 2003, 85 , 1539-1546.
25. Sastre, M.; Calero, M.; Pawlik, M.; Mathews, P. M.; Kumar, A. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol. Aging 2004, 25, 1033-1043.
26. Carrette, O.; Demalte, I.; Scherl, A.; Yalkinoglu, O.; Corthals, G. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomic 2003, 3, 1486-1494.
27. Janowski, R.; Kozak, M.; Jankowska, E.; Grzonka, Z.; Grabb, A. Human cystatin C, an amyloidogenic protein, dimerizes through threedimensional domain swapping. Nat. Struct. Biol. 2001, 8 , 316-320.
28. Mares, J.; Stejskal, D.; Vavrouskova, J.; Urbanek, K.; Herzig, R. Use of cystatin C determination in clinical diagnostics. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub. 2003, 147 , 177-180.
29. Jaskolski, M. 3D domain swapping, protein oligomerization, and amyloid formation. Acta Biochim. Pol. 2001, 48 , 807-827.
30. Serpell, L. C.; Blake, C. C.; Fraser, P. E. Molecular structure of a fibrillar Alzheimer's A beta fragment. Biochemistry 2000, 39, 13269- 13275.
31. Tycko, R. Insights into the amyloid folding problem from solid-state NMR. Biochemistry 2003, 42, 3151-3159.
32. Petkova, A. T.; Ishii, Y.; Balbach, J. J.; Antzutkin, O. N.; Leapman, R. D. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 , 16742-16747.
33. Pike, C. J.; Walencewicz-Wasserman, A. J.; Kosmoski, J.; Cribbs, D. H.; Glabe, C. G. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 1995, 64 , 253-265.
34. Miravalle, L.; Tokuda, T.; Chiarle, R.; Giaccone, G.; Bugiani, O. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J. Biol. Chem. 2000, 275 , 27110-27116.
35. Ghiso, J.; Frangione, B. Amyloidosis and Alzheimer's disease. Adv. Drus Delivery Rev. 2002, 54 , 1539-1551.
36. Esler, W. P.; Stimson, E. R.; Ghilardi, J. R.; Lu, Y. A.; Felix, A. M. Point substitution in the central hydrophobic cluster of a human betaamyloid congener disrupts peptide folding and abolishes plaque competence. Biochemistry 1996, 35, 13914-13921.
37. Wahlbom, M.; Wang, X.; Lindstrom, V.; Carlemalm, E.; Jaskolski, M. Fibrillogenic oligomers of human cystatin C are formed by propagated domain swapping. J. Biol. Chem. 2007, 282 , 18318- 18326.
38. Levy, E. Cystatin C: a potential target for Alzheimer's treatment. Expert Rev. Neurother. 2008, 8 , 687-689.
39. Dalboge, H.; Jensen, E. B.; Tottrup, H.; Grubb, A.; Abrahamson, M. High-level expression of active human cystatin C in Escherichia coli. Gene 1989, 79 , 325-332.
40. Damoc, E.; Youhnovski, N.; Crettaz, D.; Tissot, J. D.; Przybylski, M. High resolution proteome analysis of cryoglobulins using Fourier transform-ion cyclotron resonance mass spectrometry. Proteomics 2003, 3 , 1425-1433.
41. Comeau, S. R.; Gatchell, D. W.; Vajda, S.; Camacho, C. J. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 2004, 32 , W96-W99.
42. Tovchigrechko, A.; Vakser, I. A. GRAMM-X public Web server for protein-protein docking. Nucleic Acids Res. 2006, 34 , W310-W314.
43. Koradi, R.; Billeter, M.; Wuthrich, K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics 1996, 14 , 51-55, 29-32.